Dergiler / art / 2020 / Cilt: 35 - Sayı: 2

Does Abatacept Induce Testicular Toxicity?

Dergi
art
Sayfa
220–225
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further fertility and testicular toxicology evaluations including semen analysis and gonadal hormones should be performed to clarify our findings.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: This study aims to demonstrate the effect of subcutaneous injections of abatacept on the histology of testes in mice.
📊
Temel Bulgular & Veri:Materials and methods: The study included 20 male BALB/c mice (average weight, 25 g; aged 12-14 weeks).
💡
Sonuç & Katkı:Further fertility and testicular toxicology evaluations including semen analysis and gonadal hormones should be performed to clarify our findings.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: This study aims to demonstrate the effect of subcutaneous injections of abatacept on the histology of testes in mice. Materials and methods: The study included 20 male BALB/c mice (average weight, 25 g; aged 12-14 weeks). Ten mice received subcutaneous (SC) injections of abatacept (0.25 mg per 25 g body weight per 0.03 mL normal saline [NS]) at zero, two, four and eight weeks. As the control group, 10 mice received SC injections of NS (0.03 mL). At the post-injection 10th week, the mice were sacrificed, and histopathological studies were conducted. Results: The results showed that 3/10 mice died of the abatacept-treated group. Testicular histology for the abatacept-treated group showed that 7/7 displayed no histopathological changes. Conclusion: To our knowledge, this is the first control-blinded study of BALB/c mice suggesting that abatacept may not have testicular toxicity. Further fertility and testicular toxicology evaluations including semen analysis and gonadal hormones should be performed to clarify our findings.

🔖

Bu Makaleye Atıf Yap

AL-MOGAIREN, S. (2020). Does Abatacept Induce Testicular Toxicity?. art, Cilt: 35 - Sayı: 2, 220–225. https://ajindex.com/articles/144411

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Codreanu C, Damjanov N. Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biologics 2015;9:1-6
  2. Schiotis RE, Buzoianu AD, Muresanu DF, Suciu S. New pharmacological strategies in rheumatic diseases. J Med Life 2016;9:227-234
  3. Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d’Elia H, Askling J, et al. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Ann Rheum Dis 2018;77:650-7
  4. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012;10:28-55
  5. Ursini F, Russo E, De Giorgio R, De Sarro G, D’Angelo S. Current treatment options for psoriatic arthritis: spotlight on abatacept. Ther Clin Risk Manag 2018;14:1053-9. 6. Østensen M. The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol 2017;10:661-9
  6. Silva CA, Bonfa E, Østensen M. Maintenance of fertility in patients with rheumatic diseases needing antiinflammatory and immunosuppressive drugs. Arthritis Care Res (Hoboken) 2010;62:1682-90
  7. Tiseo BC, Cocuzza M, Bonfa E, Srougi M, Silva CA. Male fertility potential alteration in rheumatic diseases: a systematic review. Int Braz J Urol 2016;42:11-21. 9. de Jong PH, Dolhain RJ. Fertility, Pregnancy, and Lactation in Rheumatoid Arthritis. Rheum Dis Clin North Am 2017;43:227-37. 10. Østensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008;47:28-31. 11. Østensen M. Preconception Counseling. Rheum Dis Clin North Am 2017;43:189-99
  8. Colla L, Diena D, Rossetti M, Manzione AM, Marozio L, Benedetto C, et al. Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. J Nephrol 2018;31:361-83
  9. Grosen A, Kelsen J, Hvas CL, Bellaguarda E, Hanauer SB. The influence of methotrexate treatment on male fertility and pregnancy outcome after paternal exposure. Inflamm Bowel Dis 2017;23:561-9
  10. Arifin WN, Zahiruddin WM. Sample size calculation in animal studies using resource equation approach. Malays J Med Sci 2017;24:101-5
  11. Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus